Surgery plays am ajor role in the primary treatment of breast cancer. There has been a rapid development in breast surgery over the last 20 years. Breast conserving therapy is standard today for tumours up till 4c mi nd iameter, and can be used in selected cases for larger tumours after preoperative down staging with chemotherapy. Breast conserving therapy with postoperative radiotherapy gives the same long-term overall survival as mastectomy. Axillary surgery has also developed conservatively, with the introduction of the new technique of sentinel node biopsy, which offers an alternative to axillary clearance for staging of the axilla, with less morbidity.
INTRODUCTION
Surgery is am ajor cornerstone in the primary treatment of breast cancer in amajority of cases. Surgery alone or in combination with radiotherapy cures many patients, actually more than what is cured by the additional use of adjuvant endocrine or cytotoxic treatment. Having said that it must be strongly emphasised that modern breast cancer treatment is multidisciplinary and that surgery alone rarely is enough.
Therehas been arapiddevelopment of breast surgery,a nd the directioni so nt he conservation pathway both for the breast and the axilla. The reason for this is better diagnostic tools, and earlier detection of breast abnormalities. Historically one can find illustrations of breast surgery dated several hundred years back, but the modern era of breast surgery is not more than one hundred years old. Halsted is often referred to as the father of breast cancer surgery. He described the radical mastectomy in the late 1800-hundreds (1), and this method was used for the firsth alfo ft he 20th century. Hist heoryb ehindt his conceptw as that breast cancer startedl ocally in the breast, and spread along the lymphatics to lymphnodes in the axilla before reaching more distant organs. If one operated the breast and axilla together en bloc and cleared the area of all cancer macroscopically, there was ac hance for cure. Patients at that time often presented late and the tumour was often locally advanced, involving underlying muscles, and therefore the pectoral muscles were included in the resection. Despite these large resections, as ubstantial proportion of the patients recurred, and al ess mutilating approach was introduced, the modified radical mastectomy preserving the pectoral muscles, with results comparable to the Halsted operation (2). However, also an expanded radical mastectomy was developed involving sternotomy and clearance of internal mammary lymphnodes. Eventually, however, it was clearly shown that this did not affect overall survival (3). Successively breast cancer became regarded as as ystemic disease early in the development. The role of the extent of surgery was questioned and methods for breast conserving therapies were developed in the later half of the 20th century together with additional systemic therapies. This overview will briefly go through the options available today and give the rationale for their use.
DIAGNOSTIC SURGERY
The role for open surgical biopsy has dramatically diminished over the last twenty years. The diagnosis is mainly based on triple assessment including clinical examination, mammography and fine needle aspiration (FNA). FNA has ah igh specificity but lower sensitivity (4). FNA cannot, in most cytologists' hands, distinguish between in situ cancer and invasive lesions. For more accurate categorisation of the lesion, techniques such as core biopsy, ABBI system and vacuum-assisted core biopsy instruments have been developed. Core biopsy is simple, done under local anaesthesia, and has ah igh level of accuracy (5, 6). The ABBI system was developed as an alternative to open biopsy. The procedure is done under local anaesthesia, and through ar ound cannula, tissue samples up to ad iameter of 20 mm can be removed. The sensitivity and specificity of the procedure approaches 100 %(7), but has the disadvantage of positive margins and residual disease (8), and cannot therefore be used as at reatment option, only a diagnostic. The vacuum-assisted biopsy method offers ap ossibility to take several samples from the same area without having to do more than one skin puncture. Avacuum is built up around the cannula, and arotating circular knife cuts out tissue samples, which are suctioned out of the breast and collected, while the cannula is rotated and another sample taken. The reported accuracy of vacuum-assisted biopsies is high (9-11). The ABBI system and the vacuumassisted biopsy system are not readily available on all hospitals today, and therefore open surgical biopsy is still required in afew cases. It is preferable that the biopsy is done as as ector resection or wide local excision in cases where there is amammographically high suspicion of cancer, to avoid cutting through the cancer and to avoid at wo-stage procedure.
BREAST CONSERVATION THERAPY
Today there is awide acceptance of breast conservation therapy (BCT) as atreatment for early breast cancer. Large randomised trials have clearly shown that the outcome in terms of overall survival and diseasefree survival are almost identical after breast conservation and radiotherapy (12-14), as compared to mastectomy. The goals of BCT are to achieve local control and good cosmesis. This also dictates the limitations of BCT, in that it has to be areasonable relation between the breast size and the tumour size. Usually 4cmindiameter is considered to be the upper limit for the size of the tumour, but sometimes even smaller tumours will not be suitable for conservation therapy because of asmall breast. Deformities after BCT are difficult to correct, and often need plastic surgical procedures including local or distant flaps with or without prosthesis. Al ocal rotational flap can be used for prevention of deformity at the primary operation (15). For extremely large breasts ac oncomitant reduction mammoplasty can be considered.
Recent results from trials on downstaging of the primary tumour, through pre-operative chemotherapy, indicate that BCT could be used for larger tumours, that have responded to treatment (16-19). A 24 %c omplete response and 36 %p artial response was reported in the M.D. Anderson Cancer Center experience, but even among those with complete response asignificant proportion had residual disease (17). In acomparison of pre-or postoperative chemotherapy (NSABP B-18 Protocol) Wolmark et al (18) showed that in the preoperative group more women could be subjected to BCT. Despite afew more local relapses in this group, the disease-free and overall survivals were identical in the two treatment arms after nine years.
The introduction of mammography screening has imposed anew dimension to breast surgery, namely small non-palpable lesions. They put special demands on the surgeon, and the team around the surgeon. There is aneed for preoperative marking of the lesion, which can be made either by coal or aw ire, introduced stereotactically or with the aid of ultrasound. There must be apossibility for intraoperative mammography of the specimen, to check that the lesion is included in the specimen, and aclose cooperation with the pathology department. Modern breast surgery therefore is not the work of one surgeon, but rather ateam work. This has led to the development of specialised breast units.
RESECTION MARGINS
One of the main goals of breast surgery is to achieve local control of the disease. Intuitively one would expect the local recurrence rate to be higher, if residual disease is left behind. Most studies have also showed agreater risk of local relapse among patients with microscopically involved margins (20-22), although not all (23) , and there is no general consensus about the importance of involved or close margins. There is no consensus on how to measure resection margins, and the definition of close margins varies substantially in different studies. Follow-up time is important, and might be part of the explanation for different results in different studies (24) and addition of chemotherapy might delay the recurrence (24, 25) . Results from the Milan trials, comparing the extent of local excision clearly shows fewer recurrences after quadrantectomy as compared to tumour excision (26) , indicating that al ocally radical operation is important. At present the recommendation is therefore to strive for amicroscopically free margin, and to do ar eresection should this not be accomplished at the first operation. If the patient for some reason does not agree to that, ab oost dose of radiotherapy to the operation field can be of help (23).
LOCAL RELAPSE
There has been adebate on the importance of alocal relapse. The incidence of local relapses has been higher among patients undergoing breast conservation treatment as compared to mastectomy (12, 14) but the distant relapse-free and overall survival have been the same. In randomised trials alower local relapse rate has been found for BCT with radiotherapy as compared to BCT alone (12, 14, 27-30). All these studies, however, have shown the same survival. In the most recent overview from the Peto group, which is only presented so far as oral presentations, there was as urvival differenceb etween the radiotherapy arm and the one without, in absolute figures 3%,which was statistically significant. In the previous report this difference, however, was opposed by higher death rates from cardiovascular disease in the group given radiotherapy (31, 32) (33) showed that radiotherapy lowered the risk of local relapse, but that the effect diminished over time. The risk of having alocal relapse ten years after primary treatment was the same in the groups with and without radiotherapy. Alocal relapse rate of one percent per year has been widely accepted as an acceptable quality measure. Ar ecent study on the results of breast conserving therapy outside clinical trials in Sweden has shown, however, that the yearly rate was higher, both among women who had received radiotherapy, 17.8 %a fter 10 years, and among those who had not, 32.8 %after 10 years (34) . Another finding from that study was that as many as 30 %ofthe patients did not receive radiotherapy, despite widely accepted recommendations to give such supplementation. There was also atime trend for worse results in the later study period. Wider indications for breast conserving therapy over time might account for that finding. The selection of patients who could do well without radiotherapy obviously failed. The present recommendation is therefore to give radiotherapy to most women after breast conserving therapy to avoid local relapse. Apossible exception could be old women with non-comedo, non-lobular unifocal cancers (35) .
Adjuvant treatment with Tamoxifen lowers the rate of local recurrence (36, 37) as does chemotherapy (36, 38) . Alocal relapse is apredictor of bad prognosis (39) (40) (41) . The location in the breast of the recurrence is of importance, skin recurrences having the worst prognosis, comparable to skin recurrences after mastectomy, and recurrences in the same area as the primary tumour the best (41). Surgery for local relapse after breast conserving therapy and radiotherapy should in most instances include mastectomy since the rate of uncontrolled local disease is higher after anew local excision than after mastectomy (42) . In selected cases among women who have only had breast-conserving operation without radiotherapy initially, ab reast conserving approach can be used, followed by radiotherapy at the second occasion. For all patients with local relapse, asystemic adjuvant chemo-or endocrine treatment is recommended.
MASTECTOMY
Mastectomy is still the treatment of choice in women with large tumours, multicentric tumours, and in women where ag ood cosmetic result cannot be obtained from conservative methods. Some women prefer to have am astectomy, and their decision should be respected. The anticipated gain in psychosocial adjustment from breast conserving therapy, has not been measurable except for body image (43, 44) , when studied in randomised trials comparing mastectomy to BCT. However, these data are not so easy to interpret, since women accepting to participate in such atrial, might not be representative of all women, since they have already accepted that they might loose their breast. There is no gold standard for what proportion of operations should be done as BCT or mastectomy, respectively. But in areas where mammography screening is implemented, the rate of mastectomy usually does not exceed 30-40 %ofall operations for newly diagnosed breast cancer. Women who are suitable for and want an immediate or delayed reconstruction should be offered such option. The indications and techniques for reconstruction will be discussed in another paper in this issue of the journal.
AXILLARY SURGERY
Lymph node status is still one of the most powerful predictors of prognosis for breast cancer, and is important for the choice of postoperative adjuvant systemic treatment. Number of involved nodes are important as well as the number of retrieved nodes in node-negative patients (45) (46) (47) . Axillary surgery aims at receiving aproper staging of the breast cancer, and to give regional control. The standard procedure has for along time been axillary clearance including the first and second lymph node level. Usually this procedure retrieves at least 10 nodes from the axilla. The risk of missing metastases in other node locations is small (3, 48, 49) and unlikely to influence prognosis. However, axillary clearance is accompanied by substantial morbidityand thereforeother techniques for staging of the axilla have been developed.
Axillary sampling has been shown to produce results comparable to clearance in randomised trials (50, 51) in terms of long-term survival. The sensitivity of axillary sampling is high (52) when used by trained surgeons in as tandardised way. However, random sampling from the axilla performed by general surgeons may underestimate the true axillary status, leading to aw orse prognosis for the patient (47) either by leaving disease in the axilla, or through misclassification leading to under-treatment.
The sentinel node technique offers an ew option for axillary sampling. Numerous studies have confirmed the accuracy of the technique although there are till now no results available from randomised studies comparing sentinel node to axillary clearance. The sentinel node is defined as the first lymph node on the lymphatic pathway from at umour site, and is the most likely node to be involved with metas-tases. The node is identified with the aid of av ital blue dye, aradioactive tracer or acombination of the two. After the initial learning phase, identification is possible in over 90 % (53) (54) (55) (56) (57) (58) . The false negative rate has varied between different studies, and has been higher during the learning phase (54, 58) than after proper training (53, 57, 59) . The need for training of the individual surgeon was emphasised at aconsensus conference in Philadelphia 2001, and for obtaining high quality of the procedure aminimum of 20-30 operations per surgeon was suggested. Measurement of the false negative rate during the learning phase was also recommended, and should be kept under 5%before entering into use of sentinel node biopsy as the only staging procedure (60) . The future development of this technique should preferably be done within the frames of controlled clinical trials. The introduction of the sentinel node technique has given new dimensions to lymph node staging. First, it offers the possibility of finding sentinel nodes outside the axilla. The presence of extra axillary sentinel nodes differs alot between studies, and seems to be dependent on the injection technique. In trials using intralesional injections, the highest rate of extra axillary nodes have been documented (59, 61) . However, so far the clinical importance of extra axillary sentinel nodes is unclear. Secondly, amore thorough examination of this single node, including the use of immunohistochemical methods has introduced the possibility for detection of micrometastases. It is intriguing to speculate that these otherwise undetected micrometastases could account for some of the failures among patients classified as node negative. There is, however, no consensus on the importance of micrometastases detected by immunohistochemistry, neither for the prognosis nor for the choice of treatment (60) . The consensus conference strongly recommended that treatment decisions should be based on findings only with hematoxylin eosin staining, while awaiting results from specially designed studies.
FUTURE DEVELOPMENT AND CONCLUSION
Open surgical removal of the tumour in the breast will probably remain the first option in the treatment of breast cancer for af oreseeable future. There are, however, growing interest in minimally invasive methods and interesting trials going on for example using radiofrequency ablation (62) . It is much too early to draw any conclusions from such pilot studies.
Axillary surgery for staging will probably also defend its role, and the method of choice will probably be some kind of sampling, preferably sentinel node biopsy. It is, however, possible that newer techniques in molecular biology will be able to characterise tumours as accurately as traditional staging, or maybe even better, and also predict which kind of treatment will be the most appropriate for each tumour. Until then, surgery will play am ajor role in the primary treatment of breast cancer. 
